PonkenPlonken
16 hours ago
In good company:
"Under the deal, Vor Bio will issue 55.9 million common stock shares and corresponding warrants to buy an additional 69.8 million shares at a combined price of $0.99425 per share and warrant. The warrants, exercisable at $0.838 per share, might be used until 2031, hence perhaps adding $58.5 million in profits if completely used.
New investor Reid Hoffman spearheaded the fundraising with major shareholder RA Capital Management, Vor Bio. As agreed upon, each will get board representation. Hoffman called the company's trem-cel therapy which targets acute myeloid leukemia using CRISpen/Cas9 technology a hopeful development in cancer treatment."
https://en.wikipedia.org/wiki/Reid_Hoffman
https://finance.yahoo.com/news/vor-biopharma-secures-55-6m-142740239.html?guccounter=1&guce_referrer=aHR0cHM6Ly9maW52aXouY29tLw&guce_referrer_sig=AQAAAG0tuNK9MvQB11zJKjsCQuEXY65q6qJMzVa2xMmGe_UPW73P3TlZrz53TlAto0KIOzFJ1VOTQl_6hH3osmqgEEGKEQk_aQUDk2rx8achcDajSgaiFx67nHkqOXSvZcVp8ESdlQrR50KKetBIcDD94B2WvRxwy_U_Dyng_1W8jD1d